Imagine if you could get a high-detail map of a brain blockage using only a basic photo instead of a complex, expensive scan. This technology uses AI to find stroke markers in standard CT scans that usually require specialized dyes and experts to read. It allows any small-town clinic to make the same fast decisions as a major city hospital.
Stroke treatment is currently limited by the need for advanced imaging and specialist interpretation, which are unavailable in 50% of hospitals 24/7. This creates a geographic inequality in survival rates and recovery.
An AI-based diagnostic tool that evaluates all stroke treatment options using only standard non-contrast CT scans.
If you are a community hospital dealing with a lack of 24/7 imaging specialists — this project developed an AI tool that uses standard CT scans to reduce time-to-treatment by up to 60 minutes. This allows patients to receive life-saving care without needing advanced CTA/CTP imaging.
If you are a medical device company dealing with low adoption of advanced perfusion software — this project developed a deep learning layer that works on non-contrast CTs. This expands the usable market to the 50% of hospitals that cannot perform CTA imaging 24/7.
If you are a health ministry dealing with a projected 34% increase in stroke cases by 2035 — this project developed a triage system that works in any hospital. This prevents national healthcare systems from being overwhelmed by improving rural access to specialized care.
Based on available project data, specific pricing is not mentioned, but the project received EUR 2,495,415 in EU contribution to support its development and clinical trials.
Yes, the technology is designed to run in all small, mid, and major hospitals worldwide because it uses standard medical imaging available 24/7.
Based on available project data, the technology is developed by Methinks Software SL, though specific patent or licensing terms are not detailed in the summary.
It integrates with standard non-contrast CT equipment, which is already available in most hospitals, bypassing the need for contrast agents and specialized CTA/CTP practitioners.
The project period runs from 2023-02-01 to 2025-01-31, indicating the development and trial phase is currently active or concluding.
The project is led by a single Spanish SME, Methinks Software SL, with a 100% industry ratio. This lean structure suggests a fast-to-market approach focused on commercialization rather than academic research, backed by a significant EU investment of nearly 2.5 million euros.
Contact Methinks Software SL in Barcelona, Spain
Contact us to explore licensing opportunities for AI-driven stroke triage.
